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Abstract
Alzheimer’s disease (AD) is a major cause of dementia, disability, and death in the
elderly. Despite recent advances in our understanding of the basic biological mecha-
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nisms underlying AD, we do not know how to prevent it, nor do we have an approved
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disease-modifying intervention. Both are essential to slow or stop the growth in
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dementia prevalence. While our current animal models of AD have provided novel
insights into AD disease mechanisms, thus far, they have not been successfully used
to predict the effectiveness of therapies that have moved into AD clinical trials. The
Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease
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(MODEL-AD; www.model-ad.org) Consortium was established to maximize human
datasets to identify putative variants, genes, and biomarkers for AD; to generate, characterize, and validate the next generation of mouse models of AD; and to develop a
preclinical testing pipeline. MODEL-AD is a collaboration among Indiana University
(IU); The Jackson Laboratory (JAX); University of Pittsburgh School of Medicine (Pitt);
Sage BioNetworks (Sage); and the University of California, Irvine (UCI) that will generate new AD modeling processes and pipelines, data resources, research results, standardized protocols, and models that will be shared through JAX’s and Sage’s proven
dissemination pipelines with the National Institute on Aging–supported AD Centers,
academic and medical research centers, research institutions, and the pharmaceutical
industry worldwide.
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INTRODUCTION

ability of the patient population, effective engagement of target and
off-target effects, suitability of the target, face and construct validity

Evidence suggests that Alzheimer’s disease (AD), the most common

of the animal models, and others.7,8 However, the exact reasons for fail-

dementing disorder of late life, is the third leading cause of death in

ures of the clinical trials remain to be established. A recommendation of

the United States.1 An estimated 5.8 million Americans currently have

the National Institute on Aging (NIA) Alzheimer’s Research Summit in

AD and approximately 700,000 individuals over the age of 65 will

2015 was to develop and characterize novel animal models of AD that

die with AD in 2019, with another 18.5 million individuals acting as

would facilitate the development of novel AD therapies, using genetics

unpaid caregivers for those afflicted by the disease.2 Tragically, the

and systems biology to inform animal model development and subse-

progression of the disease is lengthy and there is currently no effective

quent pre-clinical drug testing.
Over the past two decades, multiple groups, including our own,

treatment.
The AD brain exhibits unique pathological alterations, including fil-

have focused on developing and characterizing genetically engineered

amentous inclusions of the microtubule-associated protein tau in neu-

rodent models of EOAD. These models have provided key insights

ronal cell bodies and processes; extracellular deposits of amyloid beta

into genes implicated in human AD and how they lead to some neu-

(Aβ) in senile plaques and within the walls of leptomeningeal/cerebral

ropathological abnormalities observed in AD with a focus on Aβ and

vessels; marked neuroinflammation and activation of innate immune

tau.9 While current models have provided critical information on bio-

cells; and synaptic and neuronal cell loss. Alois Alzheimer identified

logical mechanisms underlying Aβ and tau pathology, there have been

plaques and tangles in a patient with presenile dementia in 1906, but

a number of confounds that have limited their utility, particularly for

despite decades of research, the precise relationship among plaques,

preclinical studies assessing potential AD therapies.7 First, existing

tangles, and dementia remains unknown. Clues to understanding the

animal models have focused on EOAD, although it remains unclear

biological pathways underlying these pathological processes have been

whether the relatively uncommon EOAD cases and the more com-

provided by genetic studies of human AD.

mon LOAD cases proceed through identical disease mechanisms. Sec-

AD is generally classified as early-onset (EOAD) or late-onset

ond, most mouse models of Aβ pathology do not exhibit extensive

(LOAD), based on factors including age of onset and genetic markers.

neurodegeneration.10,11 Exceptions include the 5xFAD mouse model

The majority of cases of EOAD are caused by mutations in the amy-

of Aβ pathology, which exhibits regional-specific neurodegeneration

loid precursor protein (APP) and presenilin (PSEN1 and PSEN2) genes,

and the hTau mouse model of tau pathology.13–15 Third, to date, no

but EOAD accounts for only a small fraction of the total AD cases.

single EOAD model exhibits both Aβ and tau pathology, although the

Unlike EOAD, genetic susceptibility to LOAD is more complex with

3xTg mouse model, which in addition to EOAD mutations also contains

variations in many genes significantly associated with increased risk

a mutation in tau associated with frontotemporal dementia, devel-

of varying degree. The greatest genetic risk factor for LOAD in the

ops both plaques and hyperphosphorylated tau (Oddo et al., 2003).16

human population is the ε4 allele of apolipoprotein E (APOE), which

Fourth, most existing models significantly and ectopically overexpress

accounts for ≈30% of risk. More recently, next generation sequencing

the relevant transgenes to observe AD pathologies within a mouse’s

determined that the R47H variation in triggering receptor expressed

lifespan, which may introduce non-physiologic effects which do not

on myeloid cells 2 (TREM2) also conferred increased risk for AD.3 With

reflect human disease progression. Fifth, although many mouse mod-

an increased odds ratio for carriers second only to APOEε4 carriers,

els of Aβ and tau pathology exhibit age-related behavioral abnormal-

TREM2R47H is the second greatest known genetic risk factor for LOAD.

ities, it has proven difficult to relate these deficits to specific impair-

To date, more than 20 other genetic loci have been associated with

ments observed in human AD.8 Sixth, many models were generated on

LOAD by genome-wide association studies (GWAS), albeit these indi-

hybrid genetic backgrounds and could not be maintained in uniform

vidually confer a small increase in risk (between 1% and 3%). Candidate

genetic backgrounds due to premature lethality and seizures observed

genes in these loci fall into a variety of pathways including cholesterol

in many models,17–22 making them difficult to use for preclinical stud-

trafficking, inflammation, and endosomal recycling suggesting that AD

ies. Seventh, the use of many models has been restricted due to legal

is caused by perturbations in multiple biological processes. However,

constraints.23 Eighth, most studies have not examined the various ani-

the mechanisms by which individual or combinations of genetic risk

mal models in a side-by-side manner to directly assess reproducibil-

variants contribute to AD risk, onset, and progression are not known.

ity. Ninth, few mouse models of AD have been carefully examined for

This knowledge gap is severely hampering the development of treat-

age-related alterations in biomarkers and brain imaging abnormalities

ments for LOAD.

across the lifespan to relate to those observed in human AD.8 Finally,

Based upon EOAD studies, multiple approaches toward Aβ-directed

preclinical therapeutic testing conducted in current models and with

therapies have been developed and tested in clinical trials, including

traditional behavioral tests have failed to predict clinical efficacy for

active and passive Aβ immunization,4 γ- and β-secretase inhibitors, γ-

cognitive improvement in human clinical trials; however, the mouse

and Aβ aggregation inhibitors. Notably, these

models predicted Aβ lowering without improvements in cognition.7

strategies have thus far failed in AD clinical trials, although some of

Therefore, a critical need exists to generate multiple new models of AD,

these trials are continuing and showing some promise.6 There are

particularly LOAD, given that recent genetic and systems biology stud-

numerous potential explanations as to why these clinical trials have

ies of LOAD suggest that different pathways may contribute to disease

failed, including stage of disease targeted, mechanism of delivery, suit-

pathogenesis from those observed in EOAD.

secretase

modulators,5
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2
THE OVERARCHING PRINCIPLES OF
MODEL-AD
The major aims of MODEL-AD are to design, develop, characterize, and
distribute models for LOAD, and establish robust preclinical pipelines
for testing new therapies. Our strategy will be to generate new rodent
models, initially in the mouse. Mice will be engineered using CRISPR
and other traditional methods to carry combinations of human variants
identified using computational analyses of human datasets made available from AMP-AD, M2 OVE-AD, ADSP, ADNI, and other sources. New
models will be “staged’’ to precisely define phenotypes and the relevance to human AD. Human relevant-outcome measures particularly in
vivo imaging, blood biomarkers, and transcriptional profiling, as well as
traditional phenotyping methods including neuropathology, biochemistry, electrophysiology, and behavioral assays. Importantly, all models
and data will be made available for distribution. MODEL-AD will perF I G U R E 1 Workflow for creating and testing novel animal models
of late-onset Alzheimer’s disease

mit these mice to be distributed without imposing any additional legal

To meet this essential need, Model Organism Development

University of California, Irvine (UCI); The Jackson Laboratory (JAX);

and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD;

University of Pittsburgh (Pitt); and Sage Bionetworks. Each institute

www.model-ad.org) was established by the NIA to (1) identify novel

provides unique strengths that include a proven track record of transla-

combinations of genetic variants that increase risk for LOAD, (2)

tional neuroscience research and the 26-year-old Indiana Alzheimer’s

develop new animal models for LOAD including humanized Aβ and

Disease Center at IU; 35-year-old UCI Alzheimer’s Disease Research

tau models that recapitulate key hallmarks of the human disease, and

Center; 35-year-old University of Pittsburgh Alzheimer’s Disease

(3) develop robust preclinical testing pipelines, and identify and test

Research Center; more than eight decades of model production, phe-

novel therapeutic agents (Figure 1). Despite failures in most of the

notyping, and distribution (JAX); and a mission of open data curation

clinical trials for AD, key recent advances provide renewed optimism

and dissemination (Sage). An administrative core, steering commit-

that treatments for AD will be developed. First, dedication of new

tee, and external advisory board ensure the aims and milestones of

funds for research and development targeting AD specifically has

MODEL-AD are met. To maximize uptake of all resources created by

enabled the establishment and coordination of multi-institutional and

MODEL-AD (mice, data, protocols, etc) all data will be made available

inter-disciplinary precompetitive consortia to identify, characterize,

via the AD Knowledge Portal hosted on the Sage Synapse platform

and deliver new therapies to the clinic by 2025. In addition to the

(https://adknowledgeportal.synapse.org/), thereby expanding on an

Alzheimer’s Disease Research Centers (ADRCs) that are provid-

established data resource for the AD research community. All mice

ing patient samples and clinical data, other key consortia include

will be made available through the JAX AD Mouse Model Resource

MODEL-AD, the Accelerating Medicines Partnerships–Alzheimer’s

(www.jax.org/ad-repository).

or licensing restrictions on these models or the use of data generated.
MODEL-AD is a collaboration among Indiana University (IU);

Disease (AMP-AD), the Alzheimer’s Disease Neuroimaging Initiative
(ADNI), the Alzheimer’s Disease Sequencing Project (ADSP), the
Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease
(M2 OVE-AD),

and the Target Enablement to Accelerate Therapy

3
PRODUCTION, VALIDATION, AND
DISSEMINATION OF NEW MODELS FOR LOAD

Development for Alzheimer’s Disease (TREAT-AD) Consortium. Many
of these consortia are focused on accelerating the process to identify

A primary goal of MODEL-AD is to produce novel models for LOAD,

novel therapeutic targets, moving these targets forward, testing in

and extensively characterize them using human-relevant and trans-

preclinical models, and ultimately to delivering therapies to human

latable outcome measures. New models will be assessed side-by-side

AD patients (Figure 2). Second, many groups, including our own, are

with prominent existing models (eg, 5xFAD, APP/PS1, 3xTg-AD, and

developing novel computational approaches to interrogate large-scale

hTau). Wherever possible, models will be based on human-relevant

datasets to understand complex genetic disorders including AD.

genetic variants. Models with “humanized” alleles of loci including APP

Third, recent advances in manipulating genomes, particularly the

and MAPT (TAU), generated via genome engineering, will be used as a

development of gene editing by clustered regularly interspaced short

platform to introduce additional risk alleles. For example, the MODEL-

palindromic repeats (CRISPR) has accelerated and reduced the cost of

AD consortium have already generated humanized Aβ models, which

introducing human relevant variants in model organisms. Last, imaging

express human non-mutated Aβ in the fully natural context of the

technologies in both humans and model organisms allow for more

endogenous mouse APP gene. The resulting line, designated hAβ-KI

accurate assessment of particularly early stages of AD.

mouse model, produces human Aβ at physiological levels in all cell
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F I G U R E 2 Role of the MODEL-AD center in the system of NIH-funded consortia created to discover new treatments for Alzheimer’s disease.
AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; ADSP, Alzheimer’s Disease Sequencing Project; AMP-AD,
Accelerating Medicines Partnerships–Alzheimer’s Disease; MODEL-AD, Model Organism Development and Evaluation for Late-onset Alzheimer’s
Disease; M2 OVE-AD, Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease.

types that normally express APP, and it does so without the addition

et al., 2019).24,25 Work is under way within MODEL-AD to prioritize

of any FAD mutations or overexpression of APP or its metabolites.

the most appropriate genetic backgrounds.

Therefore, this innovative mouse overcomes many confounding vari-

A major limitation in generating new models has been the lack of

ables affecting the traditional models of AD and may provide a much

specific putative genetic variants in LOAD-relevant loci to precisely

more physiologically relevant understanding of the underlying mech-

engineer into the mouse genome. However, advances in genomics,

anisms driving AD pathology by closely recapitulating the pathological

computation, and imaging are providing large data resources to

cascade of events that occurs in the majority of human AD patients.

mine (eg, ADNI, AMP-AD, M2 OVE-AD, ADSP, and the International

Furthermore, this new model has also been engineered to permit the

Genomics of Alzheimer’s Project). These data will be leveraged to iden-

conditional ablation of the humanized APP gene, by incorporating

tify and prioritize candidate variants for animal models. Our initial

LoxP sites flanking the Aβ sequence. By the virtue of these novel

strategy is to use recent sequencing studies to aid in prioritizing vari-

features, the hAβ-KI mouse model can be used to address multiple

ants in existing GWAS loci, including genes such as ABCA7, CR1, and

previously inaccessible questions surrounding the involvement of Aβ

BIN1. Although the majority of GWAS loci have small effect sizes, our

in the pathogenesis of AD and multiple relevant genetic variants will

hypothesis is that they will work in concert with other variants to

be incorporated into this new model. The hAβ-KI model was originally

increase risk and should be assessed in a sensitized genetic context.

characterized on a mixed C57BL/6J (B6J) and C57BL/6N (B6N)

We then assess the mouse genome for sequence and functional homol-

genetic background but will also be available on B6J and B6N inbred

ogy to ensure the resulting model will faithfully reflect the genetics

lines. The IU/Jax/Pitt MODEL-AD Center has also created a humanized

of LOAD. Once existing loci have been assessed, we will incorporate

Aβ knock-in model without the loxP sites, on a C57BL6J background.

novel candidate genes and variants that may arise from the rapidly

The MODEL-AD consortium has also created an allelic series of

expanding efforts to understand the genetics of AD. We expect that

APOE variants (ε4, ε3, ε2; JAX IDs 27894, 29018, and 29017, respec-

these efforts will include modeling multiple non-coding variants and

tively) as well as mice carrying combinations of hAβ, APOE

ε4 ,

and

integrating data from expression quantitative trait locus (eQTL) studies

Trem2R47H on the B6J genetic background. Humanized MAPT alleles

and efforts to annotate the regulatory genome such as the ROADMAP

will be incorporated as soon as possible. Female and male mice from

(Real-World Outcomes Across the Alzheimer’s Disease Spectrum for

these platform strains are being characterized up to 24 months of

Better Care: Multi-Modal Data Access Platform) and ENCODE (Ency-

age using an extensive set of human-relevant assays. Additional AD-

clopedia of DNA Elements) projects for both mouse and human. The

relevant genetic variants and “humanized alleles’’ are being incorpo-

expanding availability of quantitative traits related to AD pathology

rated into the platform strains. Improved methods of in vitro fertil-

from ADNI, eQTL, and other functional studies will enable greater

ization will be used to accelerate production of animal models with

statistical power and phenotypic resolution. Importantly, such use of

different combinations of risk factors. MODEL-AD aims to generate

advanced computational strategies will facilitate the ability to infer

at least 50 new models for LOAD. Information on all available mod-

epistatic and pleiotropic networks of genes that can aid in prioritizing

els can be found on the MODEL-AD website (https://www.model-ad.

polygenic animal models.

org). Although models will be initially generated on the B6J back-

Many of the new models will be initially characterized using a pri-

ground, there is a growing appreciation that alternative or even mul-

mary screening approach that prioritizes the most promising mod-

tiple genetic backgrounds will need to be considered to maximize the

els for more extensive phenotyping using human-relevant outcome

relevance of mouse models to human LOAD (Onos et al., 2019; Neuner

measures. In some cases, the same strains will be characterized
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independently at multiple sites (eg, IU, JAX, and UCI) using standard-

ability of the test compound to normalize a behavioral phenotype, and

ized protocols to ensure reproducibility of key AD-relevant pheno-

these studies rarely used biomarkers or other clinically translational

types. This extensive phenotyping will occur at multiple ages, up to

endpoints. Young or naïve wild-type animals were often used in place

24 months of age, in male and female mice and, in addition to more

of aging animals, with the rationale that aged animals were costly and

traditional phenotyping assays (eg, behavior, biochemistry, and neu-

would minimize throughput. Critically, in many cases pharmacokinetic

ropathology), will include relevant in vivo positron emission tomog-

(PK) and pharmacodynamic data (PD) in AD models at biologically and

raphy (PET)/magnetic resonance (MR) imaging with autoradiography

pathologically relevant ages have not been evaluated and when per-

validation of tracer compounds, blood and cerebrospinal fluid (CSF)

formed they were conducted in a single sex without neuropathology.

biomarkers, synaptic physiology analyses (eg, basal synaptic transmis-

MODEL-AD is comprehensively addressing many identified con-

sion, long-term potentiation, axon excitability, and transmitter release

cerns. The consortium represents a unique opportunity to standard-

kinetics), and molecular profiling by RNA sequencing. Genomic data

ize practices and provide an established pipeline for preclinical testing

will be systematically compared to analogous human data from the

for the AD community while interrogating mechanisms of action that

AMP-AD Consortium to identify the specific disease-related pathways

failed in clinic for AD via a back-translational approach. The Preclini-

and modules modified in each strain (Pandey et al., 2019; Johnson et al.,

cal Testing Core (PTC) has established a streamlined preclinical testing

2018; Logsdon et al.,

2019).26-28

We have developed a new NanoS-

tring nCounter Mouse AD panel to specifically assess modifications of
LOAD-associated transcriptome modules that will be used in primary
screening of all new mouse strains.

strategy with go/no-go decision points allowing critical and unbiased
assessments of potential therapeutic agents (Figure 3).
The primary screen includes (1) an initial qualification of the active
pharmaceutical ingredient (API) of the compound to be tested, (2) drug

Additional phenotyping for selected lines will also include pro-

formulation optimization for dosing in mice, (3) drug stability assess-

teomics, metabolomics, and microbiome characterization. Assays are

ment in that formulation, and (4) multi-dose in vivo pharmacokinet-

designed to complement existing and forthcoming data from human

ics for the determination of appreciable blood and target tissue activ-

studies, and will systematically align the phenotypes of each mouse

ity in the disease model and at the pathologically and disease-relevant

model with corresponding human data. For example, early gene expres-

age in both sexes. Quantification of PK parameters for the parent com-

sion signatures that appear in mouse models may be present in human

pound will use standard moment theory (non-compartmental) meth-

brain samples, providing evidence for pathway dysfunction in LOAD.

ods and parameters.29 Using Cl/F and Vd/F as initial parameter esti-

The identification of such signatures in human subpopulations may

mates, nonlinear mixed effect analyses30–32 will be performed. Specifi-

further discriminate between heterogeneous etiologies within the

cally, to meet the screening criteria for this go/no-go decision, test arti-

human population. These analyses will link precise genetic variation

cles need to have low Cl/F, which affords less than or equal to twice

in the mouse model with pathological outcomes that contribute to

daily dosing, good blood–brain barrier penetration supporting appre-

LOAD, which can be further assessed in human carriers of the homol-

ciable exposure in brain tissue, appreciable brain retention, and low

ogous variants. Staged mouse cohorts can potentially clarify tempo-

serum protein binding. In the absence of this, compounds will not move

ral ordering of transcriptomic modifications that have accumulated

forward. Provided the compound meets the “go” criteria, the PK data

in human decedent cases. Such signals of disease progression will be

(eg, Cmax , Cl/F, Vd/F) will be used to inform PK/PD modeling to develop

correlated with imaging and other molecular phenotypes to find can-

the dosing paradigm for the secondary screen where appropriate dis-

didate biomarkers for early disease. Furthermore, our analysis will

ease models at the pathological ages achieves target brain exposure

help refine key disease markers present in human data that may be

levels to evaluate disease- (or symptom-) modifying effects.

confounded by phenotypic variation unrelated to LOAD. Importantly,

The secondary screen evaluates target engagement and disease-

these human/mouse comparisons will provide critical data to both

modifying activity of the test compound at multiple dose levels, in

determine the most appropriate models to use in preclinical studies

both males and females in the disease model at the pathologically rel-

and the novel targets to test as therapies for LOAD.

evant age using non-invasive in vivo PET/MRI as a pharmacodynamic
readout of cerebral changes in metabolism (18F-FDG), cerebral blood
flow (64Cu-PTSM), Aβ deposition (18F-AV45), or tau deposition (18F-

4
THE NEED FOR AN ACCESSIBLE VALIDATED
PRECLINICAL TESTING PIPELINE

AV1451). PET and MRI images will be coregistered,33 and mapped to
stereotactic mouse brain coordinates34 and volume of interest (VOI)
extracted from a mouse brain atlas. Each VOI will be analyzed for

Historically, preclinical screening of test compounds for AD used

standardized uptake value (SUV) or %ID/g according to published

behavioral endpoints in rodent models as the primary screen owing

methods.35 At the completion of the study, blood samples are collected

to a falsely perceived ease of conducting these experiments and rela-

and processed for plasma to confirm PK from the primary screen. To

throughput.8

Moreover, the rodent models used did not nec-

permit secondary confirmation for PET and autoradiography studies,

essarily have construct validity for AD, and experiments often evalu-

tissue sections will be immunostained with Aβ, tau, or neuroinflamma-

ated the ability of a test compound to reverse an acute pharmacological

tion antibodies.

tive high

deficit (eg, scopolamine-induced memory deficit) in wild-type or nor-

Plasma concentrations across animal models and dose levels will

mal animals, and frequently only in males. Other screens evaluated the

be combined with PET, autoradiography, and secondary confirmation
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F I G U R E 3 Workflow for testing compounds through the Preclinical Testing Core. API, active pharmaceutical ingredient; IU, Indiana
University; MRI, magnetic resonance imaging; PET, positron emission tomography; PITT, University of Pittsburgh School of Medicine; PK,
pharmokinetic; QC, quality control.

data for PK/PD model analysis (ie, direct effect, indirect response, sig-

novel object recognition). In this respect it is important to point out

nal transduction, etc) will be assessed for each compound.36 Only after

that behavioral outcome measures are limited and only being used

demonstrating target engagement will test compounds move to the

as tertiary screens after target engagement has been confirmed in

tertiary functional assessment.

the secondary screens, described above. Further, in lieu of a large

Tertiary screening will evaluate both dose response curve and

battery of behavioral assays for cognitive outcome measures which

dose range regiments (acute/chronic, route of administration and

have for all intents and purposes failed to translate to the clinic, the

pretreatment time) to determine disease-modifying effects of the

PTC will use improved translational assays such as electroencephalo-

test compound to normalize a disease-related functional phenotype.

gram as functional outcome measures.45,46 At the conclusion of the

Tertiary screening will include assessments of cognition (eg, working

tertiary screen, plasma and brain samples are used to confirm PK

memory) and activity measures (eg, locomotor activity, motor coor-

and brain samples are also sent for post-treatment transcriptomics

dination) to identify whether the dose range perceived to improve a

analysis.

functional (ie, memory) deficit is without any side effects that con-

This approach is innovative, first by establishing this standardized,

found the interpretation of the data or suggest a limited therapeutic

streamlined preclinical screening strategy, which has been validated,

window. Importantly, the PTC is well aware of the translational limi-

and provides access to these resources including standard operating

tations of the behavioral assays historically used to predict cognitive

procedures, all raw data along with negative and positive findings, and

improvement in mouse models (eg, water maze, fear conditioning,

hands-on training opportunities to the AD research community.
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5
SCREENING THE OPTIMAL
PHARMACEUTICAL FOR ALZHEIMER’S
DISEASE (STOP-AD)

neurodegeneration varies by strain and, in mapping populations, specific genetic factors. Alignment of multiscale phenotypes (molecular,
histological, and behavioral) of these models to human data will likely
identify key pathways and processes that drive neuropathology and

The PTC supports preclinical screening of test compounds nominated

LOAD. Of note, while much of LOAD is driven by the interaction

by the greater research community through its streamlined preclinical

between aging and genetics, there is a considerable influence of

screening strategy in mouse models developed and characterized by

environmental factors, much of which will not be modeled or explored

the Disease Modeling Project (DMP). Researchers can apply through

by this consortium. However, MODEL-AD will provide the next gener-

the STOP-AD portal (www.STOPADportal.synapse.org). Compounds

ation of mouse models to the research community where the impact

selected for screening will be conducted within the PTC labs at Indiana

of environment, such as diet, stress, social isolation/environmental

University and the University of Pittsburgh. Submitters are required to

enrichment, the microbiome, and other influences can be determined

provide detailed data and information about the compound they wish

and subsequently used to develop animal models of LOAD in additional

to nominate. A review panel consisting of experts in pharmacology,

species.

pharmacokinetics, neuroscience, animal model systems, behavioral
pharmacology, preclinical imaging, genetics, and AD will provide a

CONFLICTS OF INTEREST

composite score based on novelty of science, relevance of target for

The authors declare no conflicts of interest.

AD, chemical properties of the compound including optimal drug-like
properties, and quality of the data available for assessment. Selected
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